В канадском исследовании, опубликованном в журнале «JAMA Network Open», сообщается, что продающиеся в розничной торговле жевательные конфеты с ТГК могут ухудшать контроль над полосой движения и время реакции через два и пять часов после приема — даже при нормальном уровне ТГК в крови ...
Сообщение Planet-Today.com. Перевод заголовка и краткого описания выполнен автоматически.
A Canadian clinical trial published in JAMA Network Open reports that commercially sold THC gummies can worsen lane control and reaction time two and five hours after a dose — even when blood THC stays at or below the cutoffs many U.S. states use for roadside enforcement. The finding lands in the middle of a separate federal fight over how marijuana should be scheduled, tested, and policed on American roads.
Key Takeaways by Planet Today
What the trial measured: In 40 regular cannabis users, 10 mg and 20 mg THC edibles raised weaving (standard deviation of lateral position) at two and five hours versus placebo. A 2 mg dose did not produce a statistically clear lane-control effect.
Why blood tests may miss it: Peak whole-blood THC averaged 1.6 ng/mL after 10 mg and 3.4 ng/mL after 20 mg — near or below the 5 ng/mL per se line used in several jurisdictions. Impairment and blood concentration did not move together the way they do with alcohol.
What that implies for law: Per se THC limits were built largely around smoked cannabis. Edibles absorb more slowly, last longer, and can leave drivers impaired while a blood draw still looks “legal.”
The policy collision: In April 2026 the Justice Department moved FDA-approved and state-licensed medical marijuana products to Schedule III. Recreational cannabis remains Schedule I. A broader rescheduling hearing closed in mid-July; a final DEA decision has not been issued.
The open safety question: Trucking and other transport groups argue there is still no widely accepted roadside test for cannabis impairment. Researchers say the same gap is why edibles complicate enforcement more than smoked products.
What the New Trial Actually Did
The paper, published August 31, 2026 in JAMA Network Open, is a randomized, double-blind, placebo-controlled crossover trial run at the Centre for Addiction and Mental Health in Toronto between September 2024 and April 2025. Lead author Bernard Le Foll and colleagues enrolled healthy adults aged 19 to 45 who already used cannabis regularly, including edibles. Forty participants — 20 women and 20 men, mean age 30.4 — completed four sessions a week apart.
Each session used commercially styled gummies at one of four THC doses: 0 mg (placebo), 2 mg, 10 mg, or 20 mg. Participants then drove a Virage VS500M simulator at two hours, five hours, and 24 hours. The primary outcome was standard deviation of lateral position, or SDLP — a standard laboratory measure of how much a driver weaves within a lane. Secondary measures included reaction time and speed variability.
Relative to placebo, SDLP rose by 2.0 centimeters at 10 mg and 3.3 centimeters at 20 mg. Those numbers look small on a page. Traffic-safety researchers often treat an SDLP increase around 2.4 centimeters as comparable to a blood-alcohol concentration near 0.05 percent. The 2 mg dose did not clear the statistical bar for lane weaving. At 20 mg, reaction time slowed and speed became less steady. Willingness to drive fell as the dose rose. By 24 hours, almost all of the driving deficits had faded.
Whole-blood THC peaked at about 1.6 ng/mL after 10 mg and 3.4 ng/mL after 20 mg. That is the sentence that turned a laboratory paper into a policy story. Several U.S. states use per se windows in the 1 to 5 ng/mL range. Canada and other jurisdictions have used 2 or 5 ng/mL cutoffs. In this trial, people were measurably worse at holding a lane while their blood numbers sat inside, or just under, those lines.
The study was funded by a Public Safety Canada grant. Indiva supplied placebo edibles in kind. Two authors disclosed outside grants or fees from pharmaceutical or cannabis firms, including Canopy Growth and Indivior, separate from this protocol. Those disclosures belong in any honest account of the paper; they do not, by themselves, cancel the crossover design or the dose response.
What Mainstream Coverage Emphasized
The New York Times, Fox News, MedicalXpress, Psychiatric Times, and The Epoch Times all treated the result as a public-safety finding rather than a morality play. The Times quoted Le Foll saying the data “clearly show that it’s affecting driving ability, and the more you take, the more the impact,” and that users sometimes claim they drive better after cannabis. CAMH co-author Christine Wickens put the same point in plainer language in the hospital’s August 31 statement: many people may underestimate how edibles affect driving, and common retail doses can change skills that matter on the road.
Mainstream write-ups generally stayed inside the trial’s own limits. The sample was small, as most tightly controlled driving trials are. Everyone in the analysis already used cannabis. The drives were rural simulator runs with few extra distractions. The study did not fill in the hours between five and 24. It did not test teenagers, older adults, first-time users, or people taking cannabis only for medical symptoms. Those caveats appeared in the paper and in responsible secondary coverage.
Naveen Athrappully’s Epoch Times report, published September 2, 2026, tracked the CAMH numbers and then connected them to U.S. rescheduling and to the American Trucking Associations. That pairing is editorial framing, not a finding inside the JAMA tables. The tables themselves do not mention the Controlled Substances Act. They do show a timing problem that any traffic lawyer already knows: smoked THC spikes fast in blood; swallowed THC does not.
What Other Research Adds — and Where It Disagrees
This is not the first edible-and-driving study, and the literature is not a single straight line.
On April 20, 2026, the University of Colorado Anschutz Medical Campus summarized simulator work from the Colorado School of Public Health. In those sessions, people drove before and after using cannabis. Inhaled products produced smaller and less consistent changes. Edibles produced clearer problems: slower speeds, more lane variability, more lane departures. Occasional users looked worse than daily users, which is what tolerance would predict.
A separate JAMA Network Open crossover trial published May 1, 2026, from Johns Hopkins, looked at edibles plus alcohol. Combining the two made driving worse than either substance alone. Impairment after 0.05 percent breath alcohol plus 10 mg THC looked similar to 0.08 percent alcohol by itself. That paper matters because real roads do not isolate one drug at a time.
Earlier edible work has been mixed. A CAMH-linked study of participants’ own retail edibles, averaging about 7.3 mg THC, found slower mean speed at two hours but no clear change in weaving or reaction time after multiple-comparison corrections. Blood THC sat near 2.8 ng/mL. People still said they felt altered for hours and were less willing to drive. A University of Saskatchewan program with young, less experienced users and 10 mg gummies reported more simulator crashes as the session wore on, with cognitive scores worst early and still not fully normal at six hours.
The honest synthesis is narrower than either a panic headline or a dismissal. Dose matters. Route matters. Experience matters. A 2 mg gummy in a regular user did not move the main lane-control metric in the new trial. Ten and 20 mg did, for hours. Blood THC was a weak proxy for that impairment. That last sentence is the part police departments cannot wish away.
The Federal Scheduling Fight Running in Parallel
On April 23, 2026, the Justice Department and the Drug Enforcement Administration announced an order placing two categories of products in Schedule III of the Controlled Substances Act: FDA-approved drugs that contain marijuana, and marijuana products covered by a qualifying state medical-marijuana license. Acting Attorney General Todd Blanche signed the order under treaty-implementation authority, following President Trump’s December 18, 2025 executive order on medical marijuana and cannabidiol research.
Schedule III is the same basket as products such as ketamine and anabolic steroids: accepted medical use, lower abuse ranking than Schedule I or II, still controlled. The April order did not legalize recreational cannabis. Adult-use marijuana remains Schedule I at the federal level. That distinction is routinely flattened in political argument and should not be flattened here.
The same announcement opened an expedited administrative hearing on whether marijuana more broadly should move from Schedule I to Schedule III. That hearing ran from June 29 to about July 14–15, 2026. Post-hearing briefs were due in mid-August. As of early September 2026, the administrative law judge had not issued a public recommended decision, and DEA Administrator Terry Cole had not signed a final rule on full rescheduling. Industry and legal newsletters describe a recommendation that could arrive later in 2026, with a final agency action possibly sliding into 2027 if litigation intervenes.
Supporters of rescheduling say Schedule I blocks research, banks, and tax treatment, and that medical programs already exist in most states. Opponents say youth access, product potency, and impaired driving have not been solved and should not be treated as solved by a scheduling code. Both claims can be true at once. A scheduling change is not a roadside test.
What Transport Groups Are Asking For
The American Trucking Associations does not take a formal position on legalization. It does take a position on testing. In an April 24, 2026 statement, vice president of safety policy Brenna Lyles said the group was reviewing the DEA announcement and was concerned about rescheduling “without clear safeguards to preserve USDOT’s testing authority for safety-sensitive workers.”
“Absent clear protections for USDOT’s marijuana testing authority, a policy shift could undermine the Department’s drug- and alcohol-testing program and weaken highway safety. That risk is compounded by the lack of a reliable, widely accepted standard to measure marijuana impairment, whether roadside or before a driver gets behind the wheel.”
On June 29, as the broader DEA hearing opened, ATA led a 19-organization letter to Justice, DEA, HHS, and Transportation. The coalition — trucking, rail, aviation, pipeline, and related groups — asked agencies to lock in marijuana testing for safety-sensitive jobs, keep HHS lab certification aligned with DOT rules, and write a coordinated plan for what rescheduling does to commercial drivers, pilots, controllers, and rail crews. ATA has also noted that marijuana accounts for a large share of positive DOT drug tests among commercial drivers.
That is a labor-and-logistics argument, not a laboratory argument. It sits next to the JAMA paper rather than inside it. The paper shows why a blood number can be a poor stand-in for edible impairment. The trucking letter shows why regulators who rely on urine or blood panels are nervous about changing the legal status of the same molecule without a replacement tool.
How Alternative and Industry Voices Read the Same Data
Cannabis-industry and drug-policy outlets tend to accept that high-dose edibles can impair driving and then pivot to the measurement problem. Their usual points, stated fairly: smoked-cannabis blood curves should not be copy-pasted onto gummies; occasional users and daily users are not the same driver; per se laws can charge people who are no longer impaired and miss people who are; field sobriety and vehicle-based measures may be more relevant than a single nanogram cutoff.
Skeptical or restriction-minded outlets, including parts of conservative and public-safety media, use the same trial as evidence that legalization ran ahead of enforcement science. Their usual points, also stated fairly: retail 10 mg servings are not a trivial dose; five hours is a long window for someone who ate a gummy at lunch and drove home in traffic; simulator impairment is not a crash count, but SDLP is a validated surrogate used for alcohol and medicines; “I feel fine” is not a test.
Neither camp owns the methods. A crossover trial with placebo and three active doses is stronger evidence than an anecdote and weaker evidence than a multi-site on-road study with crash outcomes. Readers can hold both facts without joining a team.
What the Study Does Not Settle
It does not measure real crashes. It does not tell a state legislature what the “right” nanogram line is, because the whole point is that the line and the impairment can diverge. It does not prove that 2 mg is always safe, only that this sample of regular users did not show a clear SDLP change at that dose under these conditions. It does not prove that medical patients on a stable oral regimen drive like the recreational users in Toronto. It does not resolve whether Schedule III medical products should change DOT testing. Those are separate questions that people keep welding together because they share a plant.
The invited JAMA commentary published the same day framed the paper as a policy problem as much as a pharmacology problem: edible cannabis, blood THC, and impaired-driving law are not currently speaking the same language.
Where the Evidence Points From Here
If the Toronto results hold in larger samples, three practical consequences follow.
First, public advice that treats “wait until you feel normal” as enough is thin. In this trial, people did report lower willingness to drive as the dose rose, which is useful. They were still measurably worse at two and five hours at the two higher doses.
Second, roadside programs built on smoked-cannabis blood thresholds will keep producing false comfort and false alarms when the product is a gummy. That is an engineering and legal problem, not a culture-war problem.
Third, the federal scheduling debate and the traffic-safety debate will keep talking past each other until someone funds a detection method that tracks function rather than residue. Transport groups have been saying that in letters. The new trial is saying it in centimeters of weave.
None of that requires the reader to favor prohibition or a commercial cannabis market. It requires treating a peer-reviewed dose-response as a dose-response, and treating an unfinished DEA rulemaking as unfinished.
Related Coverage on Planet Today
- Cannabidiol (CBD) in cannabis does not impair driving, landmark JAMA study shows
- The Sunscreen Paradox: UK Biobank study and what large health datasets can and cannot prove
- Singapore Unveils Living Neuron Data Center: What the Facts Actually Show
- Italy Studies Chemical Castration for Child Sex Offenders
